Skip to content

Advertisement

  • Research
  • Open Access

Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine

  • 1,
  • 1,
  • 2, 3Email author and
  • 2, 3
Malaria Journal20109:275

https://doi.org/10.1186/1475-2875-9-275

  • Received: 21 May 2010
  • Accepted: 11 October 2010
  • Published:

Abstract

Background

Artemether-lumefantrine is one of the most widely used anti-malarial drug combinations in the world with excellent tolerability and cure rates in adult and paediatric patients with uncomplicated falciparum malaria. The aim of this study was to evaluate the pharmacokinetics of artemether and its active metabolite, dihydroartemisinin, in healthy Pakistani volunteers.

Methods

Twelve healthy male Pakistani subjects, aged 20 to 50, were recruited into the study. A fixed oral combination of artemether-lumefantrine (80-480 mg) was given as a single oral dose. Frequent blood samples were collected and artemether and dihydroartemisinin were quantified in human plasma using solid-phase extraction and liquid chromatography coupled with tandem mass spectrometry. Drug concentration-time data were evaluated with non-compartmental analysis.

Results

Observed maximum concentrations (mean ± SD) of artemether and dihydroartemisinin were 184 ± 100 ng/mL and 126 ± 46 ng/mL, respectively. These concentrations were reached at 1.56 ± 0.68 hr and 1.69 ± 0.59 hr, respectively, after drug intake. The terminal elimination half-life of artemether and dihydroartemisinin were 2.00 ± 0.71 hr and 1.80 ± 0.31 hr, respectively. Apparent volume of distribution and oral clearance for artemether were estimated to 666 ± 220 L and 257 ± 140 L/hr. The same parameters were estimated to 702 ± 220 L and 269 ± 57 L/hr for dihydroartemisinin.

Conclusions

The overall pharmacokinetic properties of artemether and dihydroartemisinin in healthy Pakistani subjects are comparable to healthy subjects and patients from other populations.

Keywords

  • Artemisinin Base Combination Therapy
  • Artemether
  • Uncomplicated Falciparum Malaria
  • Lumefantrine
  • Total Drug Exposure

Background

Malaria is one of the most important infectious diseases in the world. This parasitic disease caused almost one million deaths in 2006, mostly children under the age of 5 [1]. Artemisinin is a natural anti-malarial derived from the Chinese medicinal plant Artemisia annua. The artemisinin derivatives are the most effective anti-malarial drugs available today and they have been used with success in areas with multidrug resistant Plasmodium falciparum malaria [28]. These compounds give a rapid reduction in parasite biomass and consequently a rapid resolution of symptoms [9]. Artemisinin based combination therapy (ACT) is now recommended as first-line treatment worldwide and used to treat millions of malaria patients each year.

Exafal™ is a fixed-dose ACT formulation of artemether and lumefantrine, with each tablet containing 20 mg artemether and 120 mg lumefantrine. The recommended treatment is four tablets twice a day for three days (administered at 0, 8, 24, 36, 48, and 60 hr). This anti-malarial is generally well tolerated and highly efficacious in adults and children with uncomplicated falciparum malaria [28]. Recent reports have shown lower cure rates in pregnant women with uncomplicated falciparum malaria due to lower drug concentrations of artemether, dihydroartemisinin and lumefantrine [1012]. Artemether is rapidly absorbed and extensively metabolized (i.e. demethylated) in vitro by the cytochrome P450 (CYP) enzymes CYP1A2, CYP2B6, CYP2C19 and CYP3A4 into dihydroartemisinin [13, 14]. However, no major contribution of CYP2C19 and CYP2D6 was seen in the demethylation of artemether in healthy volunteers [14]. Dihydroartemisinin (geometric mean IC50-value of 1.2 ng/mL) is intrinsically more active than artemether (geometric mean IC50-value of 4.8 ng/mL) as an anti-malarial when investigated in fresh clinical falciparum isolates on the Thai-Burmese border [15].

Different human CYP content and isoform capacity has generally been attributed to genetic factors [16]. This contributes to the wide variety in drug metabolism capacity among different individuals and populations. This is especially true for CYP3A4 and CYP2 D and drugs cleared by these isoforms might therefore be expected to show highly variable pharmacokinetics [17]. Artemether and dihydroartemisinin show large inter-individual variability in pharmacokinetic parameters. This may in some part be explained by genetic differences in different individuals and populations. Inter-ethnic variability might therefore be an important factor when accounting for inter-individual variability in drug response [18]. The pharmacokinetics of artemether and dihydroartemisinin is described in a number of different populations, such as Caucasians [19], Thais [20], Chinese [21] and Malaysians [22]. However, the pharmacokinetics of artemether and dihydroartemisinin has not yet been studied in a Pakistani population.

The objective of this study was to characterize the pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male subjects after a single oral administration of the standard fixed artemether-lumefantrine anti-malarial combination treatment.

Methods

Study site and ethical approval

Twelve healthy Pakistani male subjects aged 20 to 50 years were enrolled in this study, conducted at the Department of Pharmacology and Therapeutics, Centre for Research in Experimental and Applied Medicine (CREAM), Army Medical College, Rawalpindi, Pakistan. The study protocol was approved by the Research Ethics Committee at the National University of Sciences and Technology, Islamabad, Pakistan. The purpose of the study, potential discomfort and adverse events were carefully explained to the volunteers in their own language and written consent was obtained. Physical and laboratory examinations were performed which included screening for cardiovascular, renal, hepatic and/or gastrointestinal disorders. The exclusion criteria were clinically significant ECG abnormalities, smoking, known renal or hepatic dysfunction. None of the volunteers had a recent history (< 3 months) of taking anti-malarials or concurrent medications. Only those who wilfully consented to participate and that fulfilled all of the inclusion criteria and none of the exclusion criteria were enrolled in the study.

Study drug

Four tablets of artemether-lumefantrine (Exafal™: each tablet contains 20/120 mg artemether/lumefantrine), produced by Novartis, Karachi, Pakistan were administered as a single oral dose. The drug was taken with a glass of milk (250 mL) after an overnight fast. The volunteers were provided a high fat traditional breakfast (i.e. Cheese omelette, fried wheat flour bread, meat gravy, and lentils) one hr after the drug administration. Relative bioavailability of artemether and lumefantrine has been demonstrated to increase with more than two-fold and five-fold, respectively, when administered with a high fat (> 1.2 g) meal compared with that in fasted individuals [23, 24].

Plasma sample collection

Blood samples for drug quantification were taken from an indwelling venous canula during the first 12 hr and thereafter by direct venipuncture. Five milliliters of blood were collected on each occasion in lithium-heparinized tubes and centrifuged without delay at 2,200 g for five minutes at 4°C. The plasma was kept in polypropylene screw capped tubes at -80°C until analysed. Blood samples were taken from each individual pre-dose (0 hr) and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, and 24 hr post-dose.

Drug analysis

This study was conducted in January 2008 and plasma samples were sent on dry-ice to the Clinical Pharmacology Laboratory at the Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand for artemether and dihydroartemisinin quantification (June 2008). Artemether and dihydroartemisinin are stable for at least two years at -80°C (in-house validation data and also to be part of an upcoming WHO report from the consensus meeting on the assessment of anti-malarial drug exposure in clinical trials). Plasma samples were analysed using high throughput liquid chromatography with tandem mass spectrometry [25]. Briefly, artemether and dihydroartemisinin were extracted using solid phase extraction (Oasis HLB μ-elution plate, Waters, Milford, USA) and quantified on an API 5000™ triple quadruple mass spectrometer (Applied Biosystems/MDS SCIEX, Foster City, USA), with a TurboV ionisation source (TIS) interface operated in the positive ion mode. Stable isotope labelled artemether and dihydroartemisinin were used as internal standards. Selected reaction monitoring (SRM) was used during quantification; transitions m/z 316-163 (artemether), m/z 320-163 (stable labelled artemether), m/z 302-163 (dihydroartemisinin), and m/z 307-166 (stable labelled dihydroartemisinin). The liquid chromatographic (LC) system was an Agilent 1200 system (Agilent technologies, Santa Clara, USA). Data acquisition and quantification were performed using Analyst 1.4 (Applied Biosystems/MDS SCIEX, Foster City, USA). The lower limit of quantification (LLOQ) for both artemether and dihydroartemisinin was set to 1.43 ng/mL with a limit of detection of 0.5 ng/mL. Triplicates of quality control samples at 3.46 ng/mL, 36 ng/mL, and 375 ng/mL for artemether and dihydroartemisinin were analysed in each batch during routine drug analysis.

Pharmacokinetic analysis

Pharmacokinetic characterization of artemether and dihydroartemisinin was performed using non-compartmental analysis (WinNonlin 5.0, Pharsight Corporation, Ca, USA). Artemether was assumed to be fully transformed into dihydroartemisinin in vivo and the relative difference in molecular weights between dihydroartemisinin and artemether were used to compute the putative dose of administered dihydroartemisinin (i.e. 95.5% of artemether dose) [13]. Pharmacokinetic analysis was performed using the linear-up/log-down trapezoidal method for each individual concentration-time profile. Total drug exposure (AUC0-∞) was calculated for each subject with extrapolation to time infinity by CPREDZ, where CPRED is the predicted concentration at the time for the last observed concentration and λZ is the elimination rate constant during the terminal phase. The terminal elimination half-life (t1/2) was determined by log-linear regression of 4 to 7 observed concentrations. Maximal concentration (CMAX) and time to reach maximal concentration (TMAX) were taken directly from the observed data. Oral clearance (CL/F) and apparent oral volume of distribution (VZ/F) are also reported.

Results

The oral formulation of artemether was well-tolerated and no clinical adverse effects were observed in any of the study subjects. Artemether and dihydroartemisinin were quantified in a total of 216 plasma samples in twelve healthy Pakistani subjects after a single oral dose of artemether-lumefantrine (80/480 mg artemether/lumefantrine). Of these, 44 artemether concentrations and 52 dihydroartemisinin concentrations (not including pre-dose) were determined to be below the LLOQ. Total precision (%CV) of quality control samples during analysis were determined to 4.7%, 1.4% and 1.5% for artemether and to 3.0%, 1.6% and 0.7% for dihydroartemisinin in low, mid and high (i.e. 3.46 ng/mL, 36 ng/mL and 375 ng/mL) quality control samples.

Individual plasma concentration-time profiles were evaluated in all twelve subjects for artemisinin and dihydroartemisinin using non-compartmental analysis (Table 1). Pharmacokinetics was well described but showed large inter-individual variability. One observed concentration was considered an outlier in one subject and removed before analysis (i.e. >10-fold unexplained increase and decrease around data point six hr after dose). Individual artemether and dihydroartemisinin plasma concentration-time curves are shown in Figure 1.
Table 1

Non-compartmental analysis of artemether and dihydroartemisinin pharmacokinetics in twelve healthy Pakistani subjects

 

Artemether

Dihydroartemisinin

 

Mean ± SD

Median (range)

Mean ± SD

Median (range)

Body-weight (kg)

69.9 ± 10

69.0 (51.0-83.0)

69.9 ± 10

69.0 (51.0-83.0)

Dose (mg/kg)

1.17 ± 0.18

1.16 (0.960-1.57)

1.11 ± 0.17

1.10 (0.92-1.49)

TLAG (hr)

0.130 ± 0.23

0 (0-0.75)

0.250 ± 0.24

0.250 (0-0.75)

CMAX (ng/mL)

184 ± 100

173 (54.2-363)

126 ± 46

122 (53.7-195)

CMAX/dose (kg × ng/mL × mg)

160 ± 86

148 (34.6-299)

113 ± 38

107 (57.1-169)

TMAX (hr)

1.56 ± 0.68

1.50 (0.500-3.00)

1.69 ± 0.59

1.50 (0.750-3.00)

CL/F (L/hr)

257 ± 140

222 (119-609)

269 ± 57

246 (209-383)

CL/F (L/hr × kg)

3.89 ± 2.8

3.11 (1.57-11.9)

3.87 ± 0.74

3.70 (3.05-5.27)

VZ/F (L)

666 ± 220

651 (342-1150)

702 ± 220

643 (456-1190)

VZ/F (L/kg)

9.85 ± 4.5

8.68 (5.02-22.5)

10.1 ± 2.6

9.63 (6.61-14.6)

T1/2 (hr)

2.00 ± 0.71

1.88 (1.24-4.00)

1.80 ± 0.31

1.78 (1.34-2.20)

AUC0-LAST (hr × ng/mL)

379 ± 170

362 (128-664)

287 ± 60

303 (196-361)

AUC0-∞ (hr × ng/mL)

385 ± 170

370 (131-671)

294 ± 58

311 (199-365)

AUC0-∞/dose (kg × hr × ng/mL × mg)

339 ± 160

322 (83.8-638)

267 ± 48

270 (190-327)

Extrapolated AUC0-∞ (%)

1.75 ± 0.99

1.43 (0.90-4.26)

2.59 ± 2.2

1.71 (0.73-8.76)

TLAG = absorption lag time, CMAX = maximum observed plasma drug concentration, TMAX = observed time to reach CMAX, CL/F = oral clearance, VZ/F = apparent oral volume of distribution based on the terminal phase, T1/2 = terminal elimination half-life, AUC0-LAST = area under the plasma concentration time curve after the first dose to the last sampling time, AUC0-∞ = area under the plasma concentration time curve after the first dose to infinity, and Extrapolated AUC0-∞ = percentage of AUC0-∞ due to extrapolation from last measured concentration to infinity.

Figure 1
Figure 1

Pharmacokinetic profiles. Individual drug plasma concentration-time profiles for artemether (A) and dihydroartemisinin (B) in healthy Pakistani volunteers after a single oral dose of 80 mg artemether and 480 mg lumefantrine. Drug concentrations are plotted on a logarithmic scale with the base 10.

Artemether (80 mg per adult dose) was absorbed rapidly from the gastrointestinal tract with a lag-time of up to 45 minutes. Considerable fluctuations in plasma artemether and dihydroartemisinin concentrations were observed within and between patients resulting in large inter-individual variability in pharmacokinetic parameters. CMAX (mean ± SD) for artemether and dihydroartemisinin were 184 ± 100 ng/mL and 126 ± 46 ng/mL, respectively. CMAX was reached after 1.56 ± 0.68 hr for artemether and 1.69 ± 0.59 hr for dihydroartemisinin after drug administration. AUC0-∞, CL/F, VZ/F and t1/2 for artemether were 385 ± 170 hr × ng/mL, 257 ± 140 L/hr, 666 ± 220 L, and 2.00 ± 0.71 hr, respectively, while computed parameters for dihydroartemisinin were 294 ± 58 hr × ng/mL, 269 ± 57 L/hr, 702 ± 220 L, and 1.80 ± 0.31 hr, respectively. The mean percentage of total AUC0-∞ extrapolated to infinity was below 3% for both artemether and dihydroartemisinin.

Discussion

The concentration-time profiles of artemether and dihydroartemisinin were evaluated in all of the 12 healthy male Pakistani volunteers and showed similar pharmacokinetics as reported in other populations with different ethnicity (Table 2) [1922]. Artemether shows a large variability within and between different populations. Maximal drug concentration and total drug exposure of artemether and dihydroartemisinin are generally comparable between the different healthy populations. However, Na-Bangchang et al [20] report a slightly longer median artemether terminal elimination half-life but a more than five-fold longer terminal elimination half-life for dihydroartemisinin in both healthy Thai volunteers and Thai patients than reported in other populations. This results in an approximately 10-fold higher total dose-normalized exposure of dihydroartemisinin [20]. To the best of our knowledge, this long half-life has not been reproduced elsewhere. This could possibly be related to drug assay differences. Contradictory to that report, Lefevre et al [26] report similar maximum concentration and total drug exposure in 25 Thai patients with uncomplicated falciparum malaria as seen in the healthy Pakistani volunteers in this study. Total drug exposure of artemether and dihydroartemisinin was somewhat higher in Chinese patients (n = 22) compared to the healthy volunteers in this study [21]. Artemether is rapidly absorbed from the gastrointestinal tract in all populations and reached maximum concentrations within two hr. An almost simultaneous detection of the artemether and dihydroartemisinin in plasma indicates a rapid in vivo conversion of artemether into its active metabolite dihydroartemisinin.
Table 2

Pharmacokinetic parameter estimates for artemether and dihydroartemisinin in different ethnic populations after artemether administration

 

Pakistani male healthy volunteers (n = 12).

Oral single dose of 80 mg artemether a,b

[present study]

Caucasian male and female healthy volunteers

(n = 16).

Oral single dose of 80 mg artemether a,b[19]

Thai male healthy volunteers (n = 6).

Oral single dose of 200 mg artemether c[20]

Malaysian male healthy volunteers

(n = 6).

Oral single dose of 200 mg artemether c[22]

Chinese male and female patients with malaria

(n = 11).

Oral multiple doses of 80 mg artemether c,d[21]

Chinese male and female patients with malaria

(n = 11).

Oral multiple doses of 80 mg artemether a,c,d[21]

Artemether

      

CMAX (ng/mL)

184 ± 100

104 ± 40

118 (112-127)

310 ± 150

157 ± 93 e

133 ± 49 e

TMAX (hr)

1.56 ± 0.68

2.00 (1.00-4.00)

3.00 (1.00-10.0)

1.88 ± 0.21

1.73 ± 0.46 e

2.13 ± 0.49 e

CL/F (L/hr)

257 ± 140

-

-

365 ± 190

-

-

V/F (L)

666 ± 220

-

-

988 ± 520

543 ± 950 e

189 ± 130 e

T1/2 (hr)

2.00 ± 0.71

1.90 ± 0.80

3.10 (1.00-9.60)

2.00 ± 0.59

1.16 ± 0.44

0.860 ± 0.26

TLAG (hr)

0.130 ± 0.23

-

-

0.330 ± 0.13

0.480 ± 0.24 e

0.830 ± 0.37 e

AUC0-∞/dose (hr × ng/mL/mg)

4.82 ± 2.2

4.00 ± 1.7

5.50 (1.65-22.2)

3.36 ± 1.4

5.73 ± 3.1

6.36 ± 2.5

AUC0-∞ (hr × ng/mL)

385 ± 170

320 ± 140

1100 (330-4440)

671 ± 270

1830 ± 1000

2040 ± 800

Dihydro-artemisinin

      

CMAX (ng/mL)

126 ± 46

104 ± 45

379 (162-702)

273 ± 64

161 ± 63 e

105 ± 42 e

TMAX (hr)

1.69 ± 0.59

2.50 (1.00-4.00)

6.00 (2.00-12.0)

1.92 ± 0.13

1.86 ± 0.45 e

2.44 ± 0.44 e

CL/F (L/hr)

269 ± 57

-

-

-

-

-

V/F (L)

702 ± 220

-

-

-

275 ± 230 e

246 ± 99 e

T1/2 (hr)

1.80 ± 0.31

2.10 ± 0.90

10.6 (4.70-19.2)

-

0.950 ± 0.42

1.06 ± 0.25

TLAG (hr)

0.250 ± 0.24

-

-

0.290 ± 0.10

0.350 ± 0.28 e

0.820 ± 0.54 e

AUC0-∞/dose (hr × ng/mL/mg)

3.86 ± 0.76

4.33 ± 1.5

34.5 (4.35-202)

3.94 ± 1.2

9.14 ± 2.0

9.80 ± 4.5

AUC0-∞ (hr × ng/mL)

294 ± 58

331 ± 110

6590 (830-38700)

753 ± 230

2930 ± 640

3140 ± 1400

a Fixed oral combination of 80 mg artemether and 120 mg lumefantrine

b administered together with a high-fat meal

c administered on an empty stomach

d administered at 0, 8, 24 and 48 hours

e pharmacokinetic parameter estimates based on the first dose

Values are reported as mean ± SD or as median (range).

Dose normalized exposures were calculated using the published mean or median value for total exposure divided with the mean or median dose.

CMAX = maximum observed plasma drug concentration, TMAX = observed time to reach CMAX, CL/F = oral clearance, V/F = apparent oral volume of distribution, T1/2 = terminal elimination half-life, TLAG = absorption lag time, and AUC0-∞ = area under the plasma concentration time curve after the first dose to infinity.

All enzymes involved in the metabolism of drugs are regulated by genes. Because of evolutionary and environmental factors, there is a remarkable degree of genetic variability built into a population. Thus, the genetic factor represents an important cause of inter-individual variation in drug metabolism. Artemether is metabolized to its active metabolite dihydroartemisinin by the enzymes CYP1A2, CYP2B6 and CYP3A4 in humans [13, 14]. CYP3A4 is also expressed in the human small intestine where it may contribute to pre-systemic metabolic conversation of artemether into dihydroartemisinin. The high extraction ratio over the liver of artemether should contribute to a substantial first pass metabolism. A previous study has shown that the plasma concentration of artemether doubles when co-administered with a potent CYP3A4 inhibitor (i.e. ketaconazole). This demonstrates the importance of the CYP3A4 present in the mucosa cells of the gut wall and the liver [19]. A wide variation in total CYP3A4 content exists among individuals which have been attributed to both environmental and genetic factors. Therefore, drugs cleared by this isoform are expected to have highly variable pharmacokinetics [18]. However, the very large influence on pharmacokinetics of food intake considerably outweighs all other sources of variability for this drug. In a previous study, a two-fold increase in relative bioavailability of artemether has been reported when administered with a fatty meal [23]. Food intake should attenuate the large variability in oral bioavailability of artemether and reduce part of the fluctuations seen in the plasma concentration profiles. Artemether-lumefantrine was administered with a glass of milk on an empty stomach followed by a high fat breakfast one hr later in the presented study to maximize the relative bioavailability and prevent erratic absorption profiles in the healthy volunteers. Even so, there was considerable inter-individual variability.

Conclusions

In conclusion, the pharmacokinetics of artemether and dihydroartemisinin was evaluated in 12 healthy male Pakistani volunteers. Pharmacokinetics were described in this population and showed similar values as reported in other populations.

Declarations

Acknowledgements

JT and NL are part of the Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme (077166/Z/05/Z) and the PKPDia collaboration, both supported by the Wellcome Trust of Great Britain.

Authors’ Affiliations

(1)
Department of Pharmacology and Therapeutics, Army Medical College, National University of Sciences and Technology(NUST), Islamabad, Pakistan
(2)
Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
(3)
Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK

References

  1. WHO: World Malaria Report. 2008, World Health Organization, GenevaGoogle Scholar
  2. Hatz C, Soto J, Nothdurft HD, Zoller T, Weitzel T, Loutan L, Bricaire F, Gay F, Burchard GD, Andriano K, Lefevre G, De Palacios PI, Genton B: Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am J Trop Med Hyg. 2008, 78: 241-247.PubMedGoogle Scholar
  3. Adjei GO, Kurtzhals JA, Rodrigues OP, Alifrangis M, Hoegberg LC, Kitcher ED, Badoe EV, Lamptey R, Goka BQ: Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J. 2008, 7: 127-10.1186/1475-2875-7-127.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI: Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg. 2005, 99: 459-467. 10.1016/j.trstmh.2004.09.013.View ArticlePubMedGoogle Scholar
  5. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, Oa O, Griffin S, Kotab K, Suano P, Tarongka N, Ura A, Lautu D, Page-Sharp M, Wong R, Salman S, Siba P, Ilett KF, Davis TM: A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med. 2008, 359: 2545-2557. 10.1056/NEJMoa0804915.View ArticlePubMedGoogle Scholar
  6. Mueller EA, van Vugt M, Kirch W, Andriano K, Hunt P, de Palacios PI: Efficacy and safety of the six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in adolescents and adults: a pooled analysis of individual patient data from randomized clinical trials. Acta Trop. 2006, 100: 41-53. 10.1016/j.actatropica.2006.09.007.View ArticlePubMedGoogle Scholar
  7. Rahman MM, Dondorp AM, Day NP, Lindegardh N, Imwong M, Faiz MA, Bangali AM, Kamal AT, Karim J, Kaewkungwal J, Singhasivanon P: Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Trans R Soc Trop Med Hyg. 2008, 102: 861-867. 10.1016/j.trstmh.2008.05.022.View ArticlePubMedGoogle Scholar
  8. Sagara I, Diallo A, Kone M, Coulibaly M, Diawara SI, Guindo O, Maiga H, Niambele MB, Sissoko M, Dicko A, Djimde A, Doumbo OK: A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Am J Trop Med Hyg. 2008, 79: 655-661.PubMedGoogle Scholar
  9. White NJ: Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg. 1994, 88 (Suppl 1): S41-43. 10.1016/0035-9203(94)90471-5.View ArticlePubMedGoogle Scholar
  10. McGready R, Stepniewska K, Lindegardh N, Ashley EA, La Y, Singhasivanon P, White NJ, Nosten F: The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2006, 62: 1021-1031. 10.1007/s00228-006-0199-7.View ArticlePubMedGoogle Scholar
  11. Tarning J, McGready R, Lindegardh N, Ashley EA, Pimanpanarak M, Kamanikom B, Annerberg A, Day NP, Stepniewska K, Singhasivanon P, White NJ, Nosten F: Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicr Agents Chemother. 2009, 53: 3837-3846. 10.1128/AAC.00195-09.View ArticleGoogle Scholar
  12. McGready R, Tan SO, Ashley EA, Pimanpanarak M, Viladpai-Nguen J, Phaiphun L, Wustefeld K, Barends M, Laochan N, Keereecharoen L, Lindegardh N, Singhasivanon P, White NJ, Nosten F: A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated Plasmodium falciparum treatment in pregnancy. PLoS Med. 2008, 5: e253-10.1371/journal.pmed.0050253.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Navaratnam V, Mansor SM, Sit NW, Grace J, Li Q, Olliaro P: Pharmacokinetics of artemisinin-type compounds. Clin Pharmacokinet. 2000, 39: 255-270. 10.2165/00003088-200039040-00002.View ArticlePubMedGoogle Scholar
  14. van Agtmael MA, Van Der Graaf CA, Dien TK, Koopmans RP, van Boxtel CJ: The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet. 1998, 23: 429-436.View ArticlePubMedGoogle Scholar
  15. Brockman A, Price RN, van Vugt M, Heppner DG, Walsh D, Sookto P, Wimonwattrawatee T, Looareesuwan S, White NJ, Nosten F: Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg. 2000, 94: 537-544. 10.1016/S0035-9203(00)90080-4.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Wilkinson GR: Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions. Clin Pharmacol Ther. 2004, 76: 99-103. 10.1016/j.clpt.2004.04.005.View ArticlePubMedGoogle Scholar
  17. Lynch T, Price A: The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007, 76: 391-396.PubMedGoogle Scholar
  18. Wood AJ: Ethnic differences in drug disposition and response. Ther Drug Monitoring. 1998, 20: 525-526. 10.1097/00007691-199810000-00013.View ArticleGoogle Scholar
  19. Lefevre G, Carpenter P, Souppart C, Schmidli H, McClean M, Stypinski D: Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol. 2002, 54: 485-492. 10.1046/j.1365-2125.2002.01696.x.PubMed CentralView ArticlePubMedGoogle Scholar
  20. Na Bangchang K, Karbwang J, Thomas CG, Thanavibul A, Sukontason K, Ward SA, Edwards G: Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria. Br J Clin Pharmacol. 1994, 37: 249-253.PubMed CentralView ArticlePubMedGoogle Scholar
  21. van Agtmael MA, Cheng-Qi S, Qing JX, Mull R, van Boxtel CJ: Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents. 1999, 12: 151-158. 10.1016/S0924-8579(99)00063-1.View ArticlePubMedGoogle Scholar
  22. Mordi MN, Mansor SM, Navaratnam V, Wernsdorfer WH: Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers. Br J Clin Pharmacol. 1997, 43: 363-365. 10.1046/j.1365-2125.1997.00573.x.PubMed CentralView ArticlePubMedGoogle Scholar
  23. White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet. 1999, 37: 105-125. 10.2165/00003088-199937020-00002.View ArticlePubMedGoogle Scholar
  24. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Kham A, Brockman A, Singhasivanon P, White NJ, Nosten F: How much fat is necessary to optimize lumefantrine oral bioavailability?. Trop Med Int Health. 2007, 12: 195-200. 10.1111/j.1365-3156.2006.01784.x.View ArticlePubMedGoogle Scholar
  25. Hanpithakpong W, Kamanikom B, Singhasivanon P, White NJ, Day NP, Lindegardh N: A liquid chromatographic-tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma. Bioanalysis. 2009, 1: 37-46. 10.4155/bio.09.6.View ArticlePubMedGoogle Scholar
  26. Lefevre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, Gathmann I, Mull R, Bakshi R: A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg. 2001, 64: 247-256.PubMedGoogle Scholar

Copyright

© Ali et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement